Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. More Details
Undervalued with high growth potential.
Share Price & News
How has Pacira BioSciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PCRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: PCRX's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: PCRX exceeded the US Pharmaceuticals industry which returned 11.1% over the past year.
Return vs Market: PCRX underperformed the US Market which returned 52.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Pacira BioSciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StThe Pacira BioSciences (NASDAQ:PCRX) Share Price Is Up 147% And Shareholders Are Boasting About It
2 months ago | Simply Wall StWe Wouldn't Rely On Pacira BioSciences' (NASDAQ:PCRX) Statutory Earnings As A Guide
3 months ago | Simply Wall StIs Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Latest Stock Performance A Reflection Of Its Financial Health?
Is Pacira BioSciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PCRX ($63.21) is trading below our estimate of fair value ($201.33)
Significantly Below Fair Value: PCRX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PCRX is good value based on its PE Ratio (18.5x) compared to the US Pharmaceuticals industry average (23.6x).
PE vs Market: PCRX is good value based on its PE Ratio (18.5x) compared to the US market (20.4x).
Price to Earnings Growth Ratio
PEG Ratio: PCRX is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: PCRX is overvalued based on its PB Ratio (4.3x) compared to the US Pharmaceuticals industry average (3.7x).
How is Pacira BioSciences forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PCRX's forecast earnings growth (21.2% per year) is above the savings rate (2%).
Earnings vs Market: PCRX's earnings (21.2% per year) are forecast to grow faster than the US market (15.7% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PCRX's revenue (11.9% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: PCRX's revenue (11.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PCRX's Return on Equity is forecast to be high in 3 years time (22%)
How has Pacira BioSciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PCRX has a high level of non-cash earnings.
Growing Profit Margin: PCRX became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: PCRX has become profitable over the past 5 years, growing earnings by 73.7% per year.
Accelerating Growth: PCRX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PCRX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.1%).
Return on Equity
High ROE: PCRX's Return on Equity (22.7%) is considered high.
How is Pacira BioSciences's financial position?
Financial Position Analysis
Short Term Liabilities: PCRX's short term assets ($720.2M) exceed its short term liabilities ($232.1M).
Long Term Liabilities: PCRX's short term assets ($720.2M) exceed its long term liabilities ($404.6M).
Debt to Equity History and Analysis
Debt Level: PCRX's debt to equity ratio (72.1%) is considered high.
Reducing Debt: PCRX's debt to equity ratio has increased from 46.5% to 72.1% over the past 5 years.
Debt Coverage: PCRX's debt is not well covered by operating cash flow (17.7%).
Interest Coverage: PCRX's interest payments on its debt are not well covered by EBIT (2.6x coverage).
What is Pacira BioSciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PCRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PCRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PCRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dave Stack (70 yo)
Mr. David M. Stack, also known as Dave, has been the Chief Executive Officer of Pacira Pharmaceuticals Inc. Since 2007, Mr. Stack has served as Chief Executive Officer and Chairman of Pacira BioSciences, I...
CEO Compensation Analysis
Compensation vs Market: Dave's total compensation ($USD9.34M) is above average for companies of similar size in the US market ($USD5.40M).
Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.
Experienced Management: PCRX's management team is seasoned and experienced (5 years average tenure).
Experienced Board: PCRX's board of directors are considered experienced (7.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PCRX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.
Pacira BioSciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Pacira BioSciences, Inc.
- Ticker: PCRX
- Exchange: NasdaqGS
- Founded: 2006
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.726b
- Shares outstanding: 44.01m
- Website: https://www.pacira.com
Number of Employees
- Pacira BioSciences, Inc.
- 5 Sylvan Way
- Suite 300
- New Jersey
- United States
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/06 22:14|
|End of Day Share Price||2021/05/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.